A Phase 4 interventional study of therapeutic program including intermittent drug intake and multimodal rehabilitation program in Osteoarthritis, Knee, Osteoarthritis, Hip and Chronic Pain, sponsored by University Hospital, Clermont-Ferrand. Recruiting at 1 site in France. Open to participants aged 50 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-02-27.
Sponsored by University Hospital, Clermont-Ferrand · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Osteoarthritis, Knee by University Hospital, Clermont-Ferrand — 3 open to participants now, 3 under way, none of them phase 3. Osteoarthritis, Knee · University Hospital, Clermont-Ferrand.
Among the 13 studies in Osteoarthritis, Knee by University Hospital, Clermont-Ferrand, this one is the only one that started in 2023, is the only one in phase 4, and was the 10th registered.
3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.
Browse Osteoarthritis, Knee studies →3 of the 13 studies in Osteoarthritis, Knee by University Hospital, Clermont-Ferrand are open now, in 1 country. Recruiting first, the newest first:
University Hospital, Clermont-Ferrand · Sites in France
Ages 18–90
University Hospital, Clermont-Ferrand · Sites in France
Ages 40+ · Women only
By country, each count listing its studies:
Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.
This study: 50 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2023.
This study's planned enrollment of 55 is below the median of 68 across 2,719 interventional studies indexed under Osteoarthritis, Knee.
Median enrollment 60 across the 7 interventional studies, 41 across the 6 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University Hospital, Clermont-Ferrand is the lead sponsor of 859 studies on the registry; 177 are open to participants now.
1 of the studies in Osteoarthritis, Knee by University Hospital, Clermont-Ferrand that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06676189University Hospital, Clermont-FerrandComparison of Pivotal Medial Polyethylene Versus Ultra-congruent in Total Knee Arthroplasty | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Osteoarthritis, Knee by University Hospital, Clermont-Ferrand, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
There is a lack of effective analgesic treatments to help walking patients with painful hip/knee osteoarthritis. Our team therefore imagined a new strategy lying on a multimodal rehabilitation walking program with the help of a transient intake of nonsteroidal anti-inflammatory drug (NSAID). NSAIDs are indeed known to act specifically on pain at movement, but their continuous intake would induce unacceptable side effects. To optimize the benefit/risk balance, the molecule to be chosen must fit to the patient's profile, and its intake should cover only the period of interest, i.e. planned walks. Our multimodal rehabilitation program will also include physical techniques such as appropriate footwear, a patient's education aiming at reducing fear/avoidance and spotting side effects of NSAIDs, and a prescription frame to avoid any overdosing.
This clinical study is a single-center, non-randomized, open label, one-arm trial, using drugs prescribed according to their label (i.e. osteoarthritis pain), pending a reinforced monitoring of side effects.
The primary endpoint is to evaluate efficacy and tolerance of a tailored and transient administration of NSAID within a rehabilitation walking program in patients with painful hip/knee osteoarthritis.
Secondary endpoints are to evaluate the adherence to the program and the factors influencing adherence; to identify the less well tolerated conditions of treatment (one condition being one molecule for one patient profile); to identify the factors of success among a set of baseline demographic, morphometric and psychometric variables; and to study the role of central sensitization (assessed by temporal summation) on the efficacy of treatment.
Study schedule:
End-of-study visit: collection of self-reported outcomes, blood sampling (biological tolerance outcomes), and collection of last efficacy outcomes (anxiety, depression, kinesiophobia, global impression of change).
The sequence of successes will be treated in Bayesian analyses. Sequential analyses with be conducted stepwise. At each step, the decision to stop or to keep going will be taken, until a maximum of 50 cases eligible for analysis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
there is only one intervention arm and no control arm; the Bayesian analysis will be conducted under hypothetical estimates of superiority vs. control.
Drug: therapeutic program including intermittent drug intake and multimodal rehabilitation program
The prescribed NSAID molecule shall be chosen according to the patient's risk profile: * gastric/duodenal risk: age \>65, history of ulcer with remission, history of inflammatory event, current low-dose acetylsalicylic acid treatment ; * cardiovascular risk (according to Agostino scale \& SCORE); The molecule with therefore be: * no risk: niflumic acid, 250 mg per intake; * gastric/duodenal risk only: diclofenac, 50-100 mg per intake, plus lansoprazole; * cardiovascular risk only: ketoprofen, 50-100 mg per intake; * double risk: ibuprofen, 200-400 mg per intake, plus lansoprazole. For the walk test, the highest dose of diclofenac or ketoprofen will be used. Then, the patient will be free to half the dose if pain relief is achieved so. One gram of acetaminophen will be added to any NSAID intake. The number of intakes will be limited to twice a day (morning and evening) and to 10 times a week.
Success
success of the therapeutic program (defined by a 30%-increase (or more) of the monthly number of target moves from the baseline observation values, with no treatment discontinuation for NSAID side effects)
Time frame: V1 (pre-intervention visit) + 12 weeks
Self-declared physical activity (efficacy outcome)
Global Physical Activity Questionnaire (GPAQ)
Time frame: V1 (pre-intervention visit)
Self-declared physical activity (efficacy outcome)
Global Physical Activity Questionnaire (GPAQ)
Time frame: V1 (pre-intervention visit) + 6 weeks
Self-declared physical activity (efficacy outcome)
Global Physical Activity Questionnaire (GPAQ)
Time frame: V1 (pre-intervention visit) + 12 weeks
Actual physical activity (efficacy outcome)
Number of steps per day assessed by pedometer
Time frame: V1 (pre-intervention visit)
Actual physical activity (efficacy outcome)
Number of steps per day assessed by pedometer
Time frame: V1 (pre-intervention visit)+ 6 weeks
Actual physical activity (efficacy outcome)
Number of steps per day assessed by pedometer
Time frame: V1 (pre-intervention visit) + 12 weeks
Pain at walk during the two last weeks (efficacy outcome)
Visual Analogic Scale VAS (11-point numerical rating scale (from 0 = "no pain" to 10) "the worst pain imaginable")
Time frame: V1 (pre-intervention visit)
Pain at walk during the two last weeks (efficacy outcome)
Visual Analogic Scale VAS (11-point numerical rating scale (from 0 = "no pain" to 10) "the worst pain imaginable")
Time frame: V1 (pre-intervention visit) + 6 weeks
Pain at walk during the two last weeks (efficacy outcome)
Visual Analogic Scale VAS (11-point numerical rating scale (from 0 = "no pain" to 10) "the worst pain imaginable")
Time frame: V1 (pre-intervention visit)+ 12 weeks
Patient's Global Impression of Change (efficacy outcome)
7-item scale
Time frame: V1 (pre-intervention visit) + 12 weeks
kinesiophobia (efficacy outcome)
Tampa Scale of Kinesiophobia (TSK)
Time frame: V1 (pre-intervention visit) + 12 weeks
level of anxious state (efficacy outcome)
Hospital Anxiety and Depression scale (HADS)
Time frame: V1 (pre-intervention visit) + 12 weeks
level of depressive state (efficacy outcome)
Hospital Anxiety and Depression scale (HADS)
Time frame: V1 (pre-intervention visit)+ 12 weeks
impairment of renal function (tolerance outcome)
either a 15%-increase (or more) of creatininemia from baseline, or a glomerular filtration rate \<60 mL.min-1 (MDRD), or creatininemia exceeding 1.5-times the upper limit of the lab's normative values
Time frame: V0 (inclusion)
impairment of renal function (tolerance outcome)
either a 15%-increase (or more) of creatininemia from baseline, or a glomerular filtration rate \<60 mL.min-1 (MDRD), or creatininemia exceeding 1.5-times the upper limit of the lab's normative values
Time frame: V1 (pre-intervention visit) + 6 weeks
impairment of renal function (tolerance outcome)
either a 15%-increase (or more) of creatininemia from baseline, or a glomerular filtration rate \<60 mL.min-1 (MDRD), or creatininemia exceeding 1.5-times the upper limit of the lab's normative values
Time frame: V1 (pre-intervention visit)+ 12 weeks
impairment of liver function (tolerance outcome)
blood transaminase levels exceeding 2.5-times the upper limit of the lab's normative values, or the occurrence of any relevant abnormality on the liver blood parameters
Time frame: V0 (inclusion)
impairment of liver function (tolerance outcome)
blood transaminase levels exceeding 2.5-times the upper limit of the lab's normative values, or the occurrence of any relevant abnormality on the liver blood parameters
Time frame: V1 (pre-intervention visit) + 6 weeks
impairment of liver function (tolerance outcome)
blood transaminase levels exceeding 2.5-times the upper limit of the lab's normative values, or the occurrence of any relevant abnormality on the liver blood parameters
Time frame: V1 (pre-intervention visit) + 12 weeks
search for anemia (tolerance outcome)
15%-decrease (or more) of hemoglobinemia from baseline
Time frame: V0 (inclusion)
search for anemia (tolerance outcome)
15%-decrease (or more) of hemoglobinemia from baseline
Time frame: V1 (pre-intervention visit) + 6 weeks
search for anemia (tolerance outcome)
15%-decrease (or more) of hemoglobinemia from baseline
Time frame: V1 (pre-intervention visit) + 12 weeks
relevant digestive event (tolerance outcome)
persistent gastralgia despite proton-pump inhibitor treatment, or any symptom of hematemesis or rectal bleeding
Time frame: V1 (pre-intervention visit) + 6 weeks
relevant digestive event (tolerance outcome)
persistent gastralgia despite proton-pump inhibitor treatment, or any symptom of hematemesis or rectal bleeding
Time frame: V1 (pre-intervention visit) + 12 weeks
bleeding event (tolerance outcome)
any abnormal bleeding event if the prescribed NSAID (Non-steroidal anti-inflammatory drugs) is COX (Cyclo-OXygenase inhibitors)-1 selective
Time frame: V1 (pre-intervention visit) + 6 weeks
bleeding event (tolerance outcome)
any abnormal bleeding event if the prescribed NSAID (Non-steroidal anti-inflammatory drugs) is COX (Cyclo-OXygenase inhibitors)-1 selective
Time frame: V1 (pre-intervention visit) + 12 weeks
thrombotic event (tolerance outcome)
any thrombotic event if the prescribed NSAID is COX-2 selective
Time frame: V1 (pre-intervention visit) + 6 weeks
thrombotic event (tolerance outcome)
any thrombotic event if the prescribed NSAID is COX-2 selective
Time frame: V1 (pre-intervention visit) + 12 weeks
serious adverse event (SAE) (tolerance outcome)
any SAE considered as relevant by the principal investigator, and possibly due to the intervention
Time frame: V1 (pre-intervention visit) + 6 weeks
serious adverse event (SAE) (tolerance outcome)
any SAE considered as relevant by the principal investigator, and possibly due to the intervention
Time frame: V1 (pre-intervention visit) + 12 weeks
EPICES scale (Evaluation of Precariousness and Health Inequalities in Health Examination Centers) (tolerance outcome)
social precarity
Time frame: V0 (inclusion)
Pain Catastrophizing Scale (PCS) (tolerance outcome)
pain catastrophizing
Time frame: V0 (inclusion)
Tampa Scale of Kinesiophobia (TSK) (tolerance outcome)
kinesiophobia
Time frame: V0 (inclusion)
level of anxious state (tolerance outcome)
Hospital Anxiety and Depression scale (HADS)
Time frame: V0 (inclusion)
level of depressive state (tolerance outcome)
Hospital Anxiety and Depression scale (HADS)
Time frame: V0 (inclusion)
temporal summation of pain (tolerance outcome)
measurement both at the forearm ipsilateral to the most painful joint and at the skin area referred to the most painful joint; temporal summation is measured by repeated stimuli with a von Frey filament (180g).
Time frame: V0 (inclusion ) + 4 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2023 (actual). Primary completion is estimated for Apr 2028, 52 months after the start.
Of 88 non-industry phase 4 interventional studies under Osteoarthritis, Knee, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 32. This study's planned 52 months is above that.
Counting every sponsor, half of 97 studies reached it within 19 months; a quarter within 10 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Clermont-Ferrand →